The fragility index applied to liver-related trials.


Journal

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
ISSN: 0975-0711
Titre abrégé: Indian J Gastroenterol
Pays: India
ID NLM: 8409436

Informations de publication

Date de publication:
10 2019
Historique:
received: 02 11 2018
accepted: 10 09 2019
pubmed: 14 12 2019
medline: 28 5 2020
entrez: 14 12 2019
Statut: ppublish

Résumé

The goal of this manuscript was to apply the fragility index (FI), which is a statistically sound method to evaluate robustness of test results, to liver-related randomized clinical trials. The authors searched the ClinicalTrials.gov database with the following limitations: term "liver," recruitment completed, with results, interventional study type, last updated May 01, 2016, to May 01, 2017. Forty-eight trials were included and four had FI of 0. The median FI for trials moving from significance to non-significance was 6 (IQR 18; 2 to 20), while the median for trials moving from non-significance to significance was 5 (IQR 5; 4 to 9). The median number lost to follow up was 17 (IQR 42; 3 to 45). Of the 21 trials that showed statistical significance, the number lost to follow up was greater than the FI in 13 (61.90%) trials. Investigators of liver-related studies should consider adding the FI to evaluate their work.

Identifiants

pubmed: 31834616
doi: 10.1007/s12664-019-00996-x
pii: 10.1007/s12664-019-00996-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

456-459

Références

J Anaesthesiol Clin Pharmacol. 2016 Oct-Dec;32(4):421-423
pubmed: 28096569
Eur Heart J. 2017 Feb 1;38(5):346-348
pubmed: 28417139
Spine J. 2015 Oct 1;15(10):2188-97
pubmed: 26072464
J Clin Epidemiol. 2018 Feb;94:69-75
pubmed: 29132833
J Clin Epidemiol. 2014 Jun;67(6):622-8
pubmed: 24508144
Crit Care Med. 2016 Jul;44(7):1278-84
pubmed: 26963326
J Clin Epidemiol. 1990;43(2):201-9
pubmed: 2303850
J Natl Cancer Inst. 2016 Aug 10;108(8):
pubmed: 27510514
Eur Heart J. 2017 Feb 1;38(5):338-345
pubmed: 27742808

Auteurs

Chase Meyer (C)

Center for Health Sciences, Oklahoma State University, 1111 W. 17th St, Tulsa, OK, 74107, USA.

Trace E Heavener (TE)

Hospitalist, Citizens Memorial Hospital, 1500 N. Oakland Ave, Bolivar, MO, 65613, USA. trace.heavener@citizensmemorial.com.

Matt Vassar (M)

Center for Health Sciences, Oklahoma State University, 1111 W. 17th St, Tulsa, OK, 74107, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH